NSCLC (Non-small Cell Lung Carcinoma) Terminated Phase 2 Trials for Ruxolitinib (DB08877)

IndicationStatusPhase
DBCOND0103105 (NSCLC (Non-small Cell Lung Carcinoma))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02119650Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerTreatment